Moleculin Biotech (NASDAQ:MBRX – Get Free Report) and Biora Therapeutics (NASDAQ:BIOR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Insider & Institutional Ownership
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 7.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 51.1% of Biora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Moleculin Biotech and Biora Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moleculin Biotech | N/A | N/A | -$29.77 million | N/A | N/A |
| Biora Therapeutics | $892,000.00 | 0.90 | -$124.11 million | ($13.04) | -0.01 |
Profitability
This table compares Moleculin Biotech and Biora Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moleculin Biotech | N/A | -157.44% | -97.16% |
| Biora Therapeutics | N/A | N/A | -332.47% |
Analyst Ratings
This is a summary of current ratings and price targets for Moleculin Biotech and Biora Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moleculin Biotech | 0 | 0 | 2 | 0 | 3.00 |
| Biora Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Moleculin Biotech presently has a consensus target price of $24.00, suggesting a potential upside of 1,325.77%. Biora Therapeutics has a consensus target price of $23.00, suggesting a potential upside of 12,814.09%. Given Biora Therapeutics’ higher possible upside, analysts clearly believe Biora Therapeutics is more favorable than Moleculin Biotech.
Risk and Volatility
Moleculin Biotech has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Summary
Biora Therapeutics beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks.
About Moleculin Biotech
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
About Biora Therapeutics
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
